Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lyra Therapeutics Inc LYRA

Healthcare
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that... see more

Recent & Breaking News (NDAQ:LYRA)

Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis

GlobeNewswire June 30, 2021

Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis

Business Wire June 8, 2021

Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets

Business Wire June 2, 2021

Lyra Therapeutics to Present at the William Blair 41st Annual Growth Stock Conference

Business Wire June 1, 2021

Lyra Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Business Wire May 11, 2021

Lyra Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

Business Wire May 6, 2021

Lyra Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update

Business Wire April 27, 2021

Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual

Business Wire April 11, 2021

Lyra Therapeutics to Present LANTERN Phase 2 Study Results for LYR?210 in Oral Presentation at COSM 2021 Virtual

Business Wire March 29, 2021

Lyra Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update

Business Wire March 9, 2021

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile March 4, 2021

Lyra Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Business Wire March 2, 2021

Lyra Therapeutics Announces Appointment of Robert Kern, MD, as Chief Medical Officer

Business Wire February 17, 2021

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA February 10, 2021

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

PR Newswire February 1, 2021

Lyra Therapeutics Provides Corporate Update and Anticipated Milestones for 2021

Business Wire January 22, 2021

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire January 13, 2021

Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of Chronic Rhinosinusitis With and Without Nasal Polyps

Business Wire December 7, 2020

Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference

Business Wire November 12, 2020

Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Business Wire November 10, 2020